Amoxicillin base 200 mg, clavulanic acid 50 mg; excipients q.s. ad 1 tablet.
Amoxi-Tabs C®-250
Tablet Oral
Broad-spectrum antibiotic with bacterial resistance inhibitor
Formulation
Indications
For the treatment of periodontal infections caused by susceptible strains (aerobic and anaerobic bacterias). Treatment of skin and soft tissues infections caused by susceptible species of Staphylococcus spp. E. coli, Pasteurella spp. and Streptococcus spp. Treatment of respiratory tract and urinary tract infections, including those caused by susceptible species of E. coli. Osteomyelitis treatment and other bacterial complications susceptible to amoxicillin.
Dosage and Administration
1 tablet/16 kg every 8 - 12 hours for at least 3 days. Administer through oral route.
Commercial Presentation
Box x 10 tablets ,
registro SAGARPA
México Registro SAGARPA Q-0616-030
MORE VISITED PRODUCTS
